A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

  • Lee, Yong Jae; 
  • Lee, Yoo-Young; 
  • Park, Jeong-Yeol; 
  • Cho, Hyun-Woong; 
  • Lim, Myong Cheol; 
  • 외 3명
Citations

WEB OF SCIENCE

9
Citations

SCOPUS

10

초록

Background: Mismatch repair deficient (MMRd) tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. However, there is no data about the complete response (CR) rate of programmed cell death protein 1 (PD-1) blockade and surgery in subjects with MMRd surgically resectable endometrial cancer. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) in patients with surgically resectable MMRd endometrial cancer. Methods: This is a multicenter, single-arm phase II trial. A total of 30 surgically resectable MMRd endometrial cancer patients will be enrolled. Inclusion criteria include clinical stage I–IIIC2, tumor specimen that demonstrates MMRd by immunohistochemistry or microsatellite instability. Exclusion criteria include multiple primary cancers, residual adverse effects of prior therapy or effects of surgery. Patients are treated with nivolumab 480 mg intravenously every 4 weeks up to 6 months followed by standard surgery and/or adjuvant treatment. The primary endpoint of the study is clinical CR rate or pathological CR rate after treatment of nivolumab. Secondary endpoints include objective response rate, progressionfree survival, overall survival, and adverse events. Correlative studies include genomic characterization of tumors, assessment of immune infiltration of tumor microenvironment, and serial circulating cell-free DNA and immune biomarkers. © 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

키워드

Endometrial Cancer; Mismatch Repair Deficiency; PD-L1 Inhibitor
제목
A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)
저자
Lee, Yong Jae; Lee, Yoo-Young; Park, Jeong-Yeol; Cho, Hyun-Woong; Lim, Myong Cheol; Kim, Mi Kyung; Lee, Jong-Min; Lee, Jung-Yun
DOI
10.3802/jgo.2025.36.e35
발행일
2025-05
유형
Article
저널명
Journal of Gynecologic Oncology
권
36
호
3
페이지
1 ~ 8